Atypical pathogens associated with cardiac implantable electronic device infections

Utkarsh Kohli MD1,2 | Aniruddha Hazra MD3 | Ahmed Shahab MD4 | Andrew D. Beaser MD4 | Zaid A. Aziz MD4 | Gaurav A. Upadhyay MD4 | Cevher Ozcan MD4 | Roderick Tung MD4 | Hemal M. Nayak MD4

1 Section of Pediatric Cardiology, Department of Pediatrics, Comer Children’s Hospital and the University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
2 Division of Pediatric Cardiology/Electrophysiology, Department of Pediatrics, West Virginia School of Medicine, Morgantown, West Virginia, USA
3 Section of Infectious Diseases & Global Health, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
4 Center for Arrhythmia Care, Heart and Vascular Center, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA

Correspondence
Hemal M. Nayak, MD, Center for Arrhythmia Care, Heart and Vascular Center, The University of Chicago Medicine, Center for Arrhythmia Care, 5841 S. Maryland Ave. MC 9024, Chicago, IL 60637, USA.
Email: hnayak@uchicago.edu

Abstract
Background: Cardiovascular implantable electronic device (CIED) infections are associated with significant morbidity and mortality making the identification of the causative organism critical. The vast majority of CIED infections are caused by Staphylococcal species. CIED infections associated with atypical pathogens are rare and have not been systematically investigated. The objective of this study is to characterize the clinical course, management and outcome in patients with CIED infection secondary to atypical pathogens.

Methods: Medical records of all patients who underwent CIED system extraction at the University of Chicago Medical Center between January 2010 and November 2020 were retrospectively reviewed to identify patients with CIED infection. Demographic, clinical, infection-related and outcome data were collected. CIED infections were divided into typical and atypical groups based on the pathogens isolated.

Results: Among 356 CIED extraction procedures, 130 (37%) were performed for CIED infection. Atypical pathogens were found in 5.4% (n = 7) and included Pantoea species (n = 2), Kocuria species (n = 1), Cutibacterium acnes (n = 1), Corynebacterium tuberculostearicum (n = 1), Corynebacterium striatum (n = 1), Stenotrophomonas maltophilia (n = 1), and Pseudozyma ahidis (n = 1). All patients with atypical CIED infections were successfully treated with total system removal and tailored antibiotic therapy. There were no infection-related deaths.

Conclusions: CIED infections with atypical pathogens were rare and associated with good outcome if diagnosed early and treated with total system removal and tailored antimicrobial therapy. Atypical pathogens cultured from blood, tissue or hardware in patients with CIED infection should be considered pathogens and not contaminants.

KEYWORDS
atypical microorganisms, cardiac implantable electronic device infection, lead extraction

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. Pacing and Clinical Electrophysiology published by Wiley Periodicals LLC
INTRODUCTION

The rate of cardiac implantable electronic device (CIED) infection has increased over the last two decades and is associated with significant morbidity and mortality. Early recognition and prompt system removal, including lead extraction, are recommended in most situations. Additionally, identification of the causative pathogenic microorganism is critical to guide appropriate antimicrobial therapy.

The vast majority of CIED infections are caused by Staphylococcal species (Staphylococcus aureus and coagulase-negative staphylococci) and represent between 60% and 80% of cases. Not only are staphylococcal CIED system infections highly virulent, but CIED infection secondary to methicillin-resistant staphylococci has become an important cause of CIED infection-related mortality. Other gram-positive cocci such as Enterococcus and Streptococcus species, gram-negative bacilli including Escherichia coli, Enterobacter and Pseudomonas species, and fungi such as Candida albicans, have previously been reported as pathogens and account for less than 15%-20% of cases. CIED infections associated with atypical pathogens are exceedingly rare and have not been systematically studied. The objective of this study is to characterize the predisposing factors, clinical course, management and outcome in patients with CIED infection secondary to atypical pathogens.

METHODS

2.1 Subjects

Medical records of all patients who underwent CIED system extraction at the University of Chicago Medical Center between January 2010 and November 2020 were retrospectively reviewed to identify patients with CIED infection. Data collection and analysis was approved by The University of Chicago Institutional Review Board. Demographic data including age, gender and ethnicity as well as clinical characteristics such as, type of CIED, duration of implant, indication for CIED implantation, and underlying comorbidities were collected. Infection specific data such as presenting clinical symptoms, lab investigations, blood, pocket, generator and lead culture results, echocardiographic findings, and outcome and follow-up details were extracted from medical records.

2.2 Definition of typical and atypical CIED infection

Typical CIED infection was defined as infection due to commonly implicated organisms such as Staphylococcus aureus and Coagulase negative staphylococci species, Streptococcus species, Enterococcus species, specific Enterobacterales (Escherichia coli, Klebsiella species, Citrobacter species, Enterobacter species, Proteus species, Serratia species), Pseudomonas species, and Candida species.

Atypical CIED infection was defined as infection due a pathogen rarely or previously not associated with CIED infections in humans. This included fastidious organisms such as the HACEK group (Haemophilus species, Aggregatibacter actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae) as well as pathogens rarely identified in CIED infections such as nontuberculous mycobacteria and fungi other than Candida. Of note, skin organisms such as Corynebacterium species, Micrococcus species, or Cutibacterium (formerly Propionibacterium) species were also considered pathogens given their infrequent association with CIED infections in isolation.

RESULTS

3.1 Demographic data

From January 2010 to November 2020, 356 CIED extraction procedures were performed at our center. Of those, 130 (37%) were performed due to CIED infection. Atypical pathogens were identified in
seven (5.4%) patients. The clinical characteristics of these 130 patients are summarized in Table 1. The majority of the study population consisted of men; approximately 30% of the study population was African-American. Over 50% of the CIED infections occurred in patients with implantable cardioverter-defibrillators (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D) devices. As expected, the study patients had many cardiovascular comorbidities. While patients with CIED infection due to typical pathogens had a higher prevalence of diabetes mellitus, there were no other major differences between the two groups.

3.2 | Pathogens associated with typical CIED infections

Coagulase-negative staphylococcus was the most commonly isolated pathogen accounting for 51% of cases (n = 66) followed by Staphylococcus aureus in 35% (n = 46). Other gram-positive organisms isolated included Streptococcus species in 1.5% (n = 2), and Enterococcus faecalis in 8% (n = 10). Gram negative organisms such as Escherichia coli, Enterobacter species, Pseudomonas species, Serratia species, and Klebsiella species were identified in 12% (n = 16). Candida species were isolated in 3% (n = 3). Polymicrobial infection was noted in approximately 19% (n = 25). Only one patient had culture negative CIED infection.

3.3 | Pathogens associated with atypical CIED infections

Seven unique pathogens were identified in seven patients: Pantoaea species (n = 2), Kocuria species (n = 1), Cutibacterium acnes (n = 1), Corynebacterium tuberculostearicum (n = 1), Corynebacterium striatum (n = 1), Stenotrophomonas maltophilia (n = 1), and Pseudozyma ahidis (n = 1). The clinical details of these and other reported patients with atypical CIED infection due to similar organisms are summarized in Table 2.

3.4 | Pantoeea species

3.4.1 | Patient 1

A 52-year-old obese man with end stage renal disease and non-ischemic cardiomyopathy presented with a systemic ICD infection with two sets of positive blood cultures growing undifferentiated Pantoaea. Transesophageal echocardiography (TEE) revealed a 3.5 cm vegetation on his ICD lead. Prior to presentation, he had been treated with intravenous vancomycin and cefepime for 12 weeks without success. He underwent extraction of his CIED system. Hardware cultures grew undifferentiated Pantoaea species and Staphylococcus haemolyticus. Both organisms were sensitive to several antibiotics. He was treated with oral trimethoprim-sulfamethoxazole for 3 months. At 4 months follow-up after his system extraction, the patient had no recurrent signs or symptoms of infection. He refused another ICD implant.

3.4.2 | Patient 2

A 26-year-old man with non-ischemic cardiomyopathy, history of ICD implant 2 years prior to presentation, and severe left ventricular dysfunction (on intravenous milrinone therapy via a peripherally inserted central catheter [PICC]) developed upper respiratory tract infection (URI) symptoms, cough, fever and rigors 3-4 weeks prior to presentation. He denied erythema, pain, or swelling at the PICC insertion site. He was hospitalized and was noted to be in septic shock. The PICC was removed and sent for culture (PICC culture was negative). Two sets of blood cultures grew Pantoaea agglomerans and he was treated with meropenem for 48 h followed by intravenous ceftriaxone. His blood cultures also grew a yeast (Pseudozyma ahidis) which was treated initially with intravenous micafungin. A TEE was performed and was notable for a bicuspid aortic valve without any significant stenosis or regurgitation and a 0.95 cm mobile vegetation on his ICD lead. He subsequently underwent extraction of his single chamber transvenous ICD system which was followed by a 6-week course of intravenous ceftriaxone and oral voriconazole. His ICD lead culture was negative. The patient was discharged home with a wearable defibrillator. At 24 months of follow-up, he continues to do well without any symptoms and signs of infection. He has refused another implant.

3.5 | Kocuria species

An 86-year-old man with previous cardiac arrest and ischemic cardiomyopathy presented with erythema, skin thinning and fixation over his CIED pocket, 10 years after initial CRT-D implant (Figure 1). Blood cultures were negative and he had no systemic symptoms. He underwent total system extraction and was treated empirically with intravenous vancomycin and cefazolin. ICD lead culture was positive for Kocuria species with no other organisms identified. A source for Kocuria infection was not found. He was switched to a 10-day course of oral dicloxacillin and was discharged with a wearable defibrillator. At 6 months of follow-up his pocket area had completely healed. He subsequently underwent another CRT-D implant at an outside hospital and has done well without reinfection.

3.6 | Cutibacterium acnes

A 17-year-old boy with a malignant flecainide, nadolol, and sympathectomy refractory catecholaminergic polymorphic tachycardia phenotype caused by a large deletion in exon three of RYR2 underwent a dual chamber transvenous ICD implantation.6 Six weeks later, he reported copious serosanguineous discharge from the ICD incision. He denied any history of fever. The patient was admitted and underwent system removal. He was discharged home on oral augmentin. Hardware and
### TABLE 1  Characteristics of patients with CIED infection

| Characteristic                                      | Patients with Typical Pathogens (n = 123) | Patients with Atypical Pathogens (n = 7) | p value |
|-----------------------------------------------------|------------------------------------------|-----------------------------------------|---------|
| **Demographics**                                    |                                          |                                         |         |
| Age (years)                                         | 65 ± 15                                  | 53 ± 25                                 | .19     |
| Men                                                 | 85 (69%)                                 | 7 (86%)                                 | .67     |
| Race                                                |                                          |                                         |         |
| Caucasian                                          | 63 (51%)                                 | 3 (43%)                                 | .66     |
| African American                                    | 48 (39%)                                 | 2 (28%)                                 |         |
| Asian                                               | 10 (8%)                                  | 1 (14%)                                 |         |
| **Clinical characteristic**                         |                                          |                                         |         |
| CIED dwell time (weeks)                             | 253 ± 228                                | 257 ± 192                               | .80     |
| Ischemic cardiomyopathy                             | 56 (45%)                                 | 2 (29%)                                 | .32     |
| Non-ischemic cardiomyopathy                         | 55 (45%)                                 | 3 (43%)                                 | .62     |
| ARVC                                                | 0                                        | 1                                       | .05     |
| Ventricular tachycardia or fibrillation             | 25 (20%)                                 | 2 (29%)                                 | .48     |
| Previous open heart surgery                         | 39 (32%)                                 | 1 (14%)                                 | .30     |
| Complete or high grade AVB                          | 33 (27%)                                 | 0                                       | .12     |
| Sick sinus syndrome                                 | 13 (11%)                                 | 0                                       | .47     |
| Congenital heart disease                            | 1 (0.8%)                                 | 1 (14%)                                 | .32     |
| Valvular heart disease                              | 12 (10%)                                 | 1 (14%)                                 | .53     |
| Peripheral vascular disease                         | 10 (8%)                                  | 0                                       | .56     |
| Atrial fibrillation                                 | 52 (42%)                                 | 3 (43%)                                 | .63     |
| History of cerebrovascular accident                 | 13 (11%)                                 | 0                                       | .47     |
| Pulmonary hypertension                              | 5 (4%)                                   | 0                                       | .75     |
| Systemic hypertension                               | 73 (59%)                                 | 3 (43%)                                 | .31     |
| Diabetes mellitus                                   | 50 (41%)                                 | 0                                       | .03     |
| Past or current tobacco use                         | 57 (46%)                                 | 4 (57%)                                 | .60     |
| Chronic obstructive pulmonary disease               | 23 (19%)                                 | 0                                       | .24     |
| Obstructive sleep apnea                              | 12 (10%)                                 | 1 (14%)                                 | .53     |
| **Laboratory & clinical data**                      |                                          |                                         |         |
| WBC count at presentation (cells/μL)                | 8.7 ± 4.6                                | 6.5 ± 1.9                               | .19     |
| Platelet count at presentation (1000/μL)           | 212 ± 92                                 | 208 ± 129                               | .53     |
| Glomerular filtration rate (mL/min/1.73m^2)        | 61 ± 30                                  | 60 ± 44                                 | .96     |
| Left ventricular ejection fraction (%)              | 39 ± 16                                  | 42 ± 20                                 | .76     |
| **Type of Device**                                  |                                          |                                         |         |
| Permanent pacemaker                                 | 36 (30%)                                 | 1 (14%)                                 |         |
| Implantable cardioverter-defibrillator              | 47 (38%)                                 | 3 (43%)                                 |         |
| S-ICD                                               | 1 (1%)                                   | 0                                       |         |
| CRT-D                                               | 35 (28%)                                 | 2 (29%)                                 | .22     |
| Other                                               | 4 (3%)                                   | 0                                       |         |
| **Infection characteristics**                       |                                          |                                         |         |
| Positive blood cultures                             | 67 (45%)                                 | 2 (29%)                                 | .25     |
| Positive hardware cultures                          | 93 (76%)                                 | 5 (71%)                                 | .68     |
| Septic shock                                        | 22 (18%)                                 | 0                                       | .60     |
| Endocarditis                                        | 36 (29%)                                 | 4 (57%)                                 | .20     |
| Pocket infection                                     | 59 (48%)                                 | 4 (57%)                                 | .72     |
| Duration of antibiotic therapy (weeks)              | 4 ± 2.2                                  | 5 ± 2.5                                 | .30     |
| Days between infection diagnosis and extraction     | 27 ± 53                                  | 26 ± 46                                 | .23     |
| Infection-related deaths                            | 22 (18%)                                 | 0                                       | 1.0     |

Abbreviations: AVB, atrioventricular block; ARVC, arrhythmogenic right ventricular cardiomyopathy; CIED, cardiac implantable electronic device; WBC, white blood cell; S-ICD, subcutaneous implantable cardioverter defibrillator; CRT-D, cardiac resynchronization therapy with a defibrillator. Values are n (%), mean ± standard deviation.
### TABLE 2  Characteristics of patients with atypical CIED infection

| Authors | Age (years) | Gender | CIED dwell time (weeks) | Comorbidities | Type of CIED | WBC Count (10^9/L) | Days between diagnosis and extraction | Endocarditis (lead or valve) | Hardware cultures | Blood cultures | Site culture | Antibiotic sensitivity utilized | Antibiotic therapy utilized |
|---------|-------------|--------|-------------------------|---------------|--------------|------------------|-------------------|-------------------------------------|----------------------------|----------------|--------------|-------------|--------------------------------|-------------------------------|
| Kohli et al | 52 | M | 359 | NICM, ESRD | ICD | 3.4 | 131 | RV lead: Pantoea species and Staphylococcus species were pansensitive. | Positive | Both Pantoea species and Staphylococcus species were pansensitive. | Vancomycin and Cefepime for 12 weeks, followed by oral TMP/SM for 3 months |
| Kohli et al | 26 | M | 208 | NICM (EF 21%) on home milrinone therapy, BAV | ICD | 5.7 | 12 | 0.95 cm mobile vegetation on ICD lead | Positive | Pseudomonas aeruginosa | Meropenem for 48 h, Ceftriaxone for 6 weeks, Micaflungin for 9 days, Metronidazole for 7 days |
| Ajam et al | 61 | F | <1 | NICM, DM, HTN on home milrinone therapy, BAV | CRT-D | 13 | A few days | – | – | – | Positive | Co-infection with Stenotrophomonas maltophilia |
| Kohli et al | 86 | M | 538 | ICM, VT, AF, OSA | CRT-D | 5.3 | 7 | – | ICD lead | – | – | Vancomycin and Cefazolin for 72 h, Dicloxacillin for 10 days |
| Kohli et al | 17 | M | 6 | Obesity, CPVT | ICD | 9.7 | 7 | – | ICD lead | – | – | Penicillin (S), Moxifloxacin (S) | Cefalexin for 4 days, Vancomycin + Cefepime for 7 days, Oral amoxicillin for 14 days followed by long term suppressive amoxicillin |
| Chalour et al | 48 | M | 262 | SSS | PPM | 12 | 15 x 8 mm mass on the RV lead | Positive | – | Penicillin (S), Amoxicillin (S), Erythromycin (S) | IV Amoxicillin X 1 month |
| Noel et al | 74 | M | 104 | AV block, DM, HTN | PPM | 15 | 11 | 6 x 3 cm mass in the right atrium | Positive | – | Amoxicillin, clavulanic acid, Gentamicin, Amoxicillin-Rifampicin for 6 weeks |

(Continues)
**TABLE 2** (Continued)

| Authors                  | Age (years) | Gender | CIED dwell time (weeks) | Comorbidities          | Type of CIED | WBC Count (10^9/L) | Days between diagnosis and extraction | Endocarditis (lead or valve) | Hardware cultures | Blood cultures | Site culture | Antibiotic sensitivity | Antibiotic therapy utilized |
|--------------------------|-------------|--------|-------------------------|------------------------|--------------|--------------------|---------------------------------------|-------------------------------|---------------------|----------------|--------------|------------------|---------------------------|
| Santo et al              | 48          | F      | 52                      | Ebstein's anomaly      | PPM          | 270                | Positive                              | Positive                       | Positive             | -              | -              |                           | Oral first generation cephalosporin |
| Gorospe et al            | 59          | M      | PPM                     |                        |              |                    |                                       |                               |                     |                |                | Penicillin (S)             |                                          |
| Kohli et al              | 55          | F      | 3                       | ARVC, VT               | ICD          | 12                 | RA lead and ICD generator              | -                             | -                   | -              |                | Penicillin (S)             |                                          |
| Melero-Bascones et al    | 73          | M      | 312                     |                         | PPM          | 28                 | Positive                              | Positive                       | Positive             | -              |                | Penicillin (R)             | IV Vancomycin (4 weeks)               |
| Oliva et al              | 71          | F      | 8                       |                         | PPM          | 11                 | Positive                              | Positive                       | (CONS)              | Positive (CONS) |                | Penicillin (R)             | Daptomycin for 4 weeks               |

(Continues)
| Authors        | Age (years) | Gender | CIED dwell time (weeks) | Comorbidities | Type of CIED | WBC Count (10^9/L) | Days between diagnosis and extraction | Endocarditis (lead or valve) | Hardware cultures | Blood cultures | Site culture | Antibiotic sensitivity | Antibiotic therapy utilized |
|---------------|-------------|--------|-------------------------|---------------|--------------|-------------------|---------------------|--------------------------------------|-----------------------------|------------------|---------------|--------------|------------------------|--------------------------|
| Abi et al     | 51          | M      | 28                      | Highgrade AVB | PPM          | 5.3               | Positive            | Positive                              | Positive                    | –                |              | Penicillin (G)          | IV Ciprofloxacin □         |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Gentamicin (S)          | Vancomycin for 6 weeks    |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Tobramycin (S)          |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Erythromycin (S)        |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Lincomycin (S)          |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Linezolid (S)           |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Chloramphenicol         |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | (S)                     |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Tetracycline (S)        |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Rifampicin (S)          |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Trimethoprim (S)        |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Sulfamethoxazole        |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | (S)                     |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Daptomycin (S)          | Daptomycin for 3 weeks    |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Penicillin (R)          |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Cefepime (R)            |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Clindamycin (R)         |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Fluoroquinolones (R)    |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | (R)                     |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | trimethoprim/Sulfamethoxazole (R) |                        |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Doxycycline (S)         |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Gentamicin (S)          |                          |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Linezolid (S)           |                          |
| Kohl et al    | 79          | M      | 100                     | HTN           | PCM          | 6.3               | 6                   | No                                    | PPM Generator, – RA and RV lead | Positive |              | Levofloxacin (S)        | Vancomycin for 48 h       |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Minocycline (S)         | Cefepime for 96 h         |
|               |             |        |                         |               |              |                   |                     |                                      |                             |                  |              | Trimethoprim/Sulfamethoxazole (S) |                        |

(Continues)
| Authors          | Age (years) | Gender | CIED dwell time (weeks) | Comorbidities                                                                 | Type of CIED | WBC Count (10^9/L) | Days between diagnosis and extraction | Endocarditis (lead or valve) | Hardware cultures | Blood cultures | Site culture | Antibiotic sensitivity | Antibiotic therapy utilized |
|------------------|-------------|--------|-------------------------|-------------------------------------------------------------------------------|--------------|--------------------|--------------------------------------|--------------------------------|---------------------|----------------|-------------|---------------|---------------------|--------------------------|
| Takigawa et al.  | 72          | F      | 884                     | AV block, Chronic refractory middle and external otitis                        | PCM          | 6.8                | 102                                  | 17 × 7 mm mobile vegetable on RA (lead) | Positive             | Positive       |              |             | TMP/SM (S)          | Vancomycin               |
|                  |             |        |                         |                                                                                |              |                    |                                      |                                |                     |                |              | Minomycin (S)        | Cefazolin (no response) |
|                  |             |        |                         |                                                                                |              |                    |                                      |                                |                     |                |              | Prazufloxacin (S)     | TMP/SM                  |
| Aktuerk et al.   | 93          | M      |                         | CRF, IHD, AF, Dementia, HTN, Polymyalgia Rheumatica (steroids)                 | PCM          | –                  | –                                    | –                              | Positive             | Positive       |              |             | –                  | –                        |
|                  |             |        |                         |                                                                                |              |                    |                                      |                                |                     |                |              | –                  |                        |
| Reynaud et al.   | 81          | F      | 68                      | HTN, AF, Rhizomelic pseudo-polyarthritides (Steroids), CRF                      | CRT-P        | –                  | 3 mobile vegetations [<10 mm] on TV   | Positive                       | –                   | Positive       |              |             | Ticarcillin-Clavulanic Acid (R) | Died 9 days after device extraction. |
|                  |             |        |                         |                                                                                |              |                    |                                      |                                |                     |                |              | Cephalosporins (R)     | Carbapenems (R)          |
| Ajam M et al.    | 61          | F      | Few days                | NICM, DM, HTN                                                                 | CRT-D        | 13                 | A few days                           | –                             | –                   | –              | –             | (Also, Pantostato)     | –                        |
|                  |             |        |                         |                                                                                |              |                    |                                      |                                |                     |                |              |                        | –                        |
| Rostoff et al.   | 22          | M      | 52                      | D-TGA, Senning procedure, AV block, CHF (NYHA IV)                              | PCM          | 5.5                | A few days                           | 6 × 16 mm vegetable on LV lead | Positive             | Positive       |              | –                  | Ticarcillin-Clavulanic Acid (S) | Died 9 days after surgical device and lead extraction. |
|                  |             |        |                         |                                                                                |              |                    |                                      |                                |                     |                |              | Trimethoprim-sulfamethoxazole (R) | –                        |
|                  |             |        |                         |                                                                                |              |                    |                                      |                                |                     |                |              | Ciprofloxacin (R)      | β-lactams (R)           |

Abbreviations: WBC, white blood cell; M, male; F, female; NICM, non-ischemic cardiomyopathy; ESRD, end stage renal disease; ICD, implantable cardioverter defibrillator; RV, right ventricle; EF, ejection fraction; CONS, coagulase negative Staphylococcus; S, sensitive; R, resistant; ICM, ischemic cardiomyopathy; VT, ventricular tachycardia; VF, ventricular fibrillation; OSA, obstructive sleep apnea; CRT-D, cardiac resynchronization therapy with a defibrillator; CPVT, catecholaminergic polymorphic ventricular tachycardia; SSS, sick sinus syndrome; PPM, permanent pacemaker; AVB, atrioventricular block; DM, diabetes mellitus; HTN, hypertension; PCR, polymerase chain reaction; ARVC, arrhythogenic right ventricular cardiomyopathy; RV, right ventricle; RA, right atrium; LVAD, left ventricular assist device; CRF, chronic renal failure; AF, atrial fibrillation; CRT-P, cardiac resynchronization therapy with a pacemaker; D-TGA, D-Transposition of great arteries; NYHA, New York Heart Association; LV, left ventricle; TV, tricuspid valve.
FIGURE 1  Cardiac implantable electronic device (CIED) pocket infection secondary to *Kocuria* species. Erythema, thinning and fixation of the skin overlying the CIED pocket are seen predominantly over the lower lateral border of the CIED pocket. Implantable cardioverter defibrillator (ICD) lead and pocket cultures were positive for *Kocuria* species with no other organisms identified. [Color figure can be viewed at wileyonlinelibrary.com]

pocket-tissue cultures grew *Cutibacterium acnes*. He was treated with oral amoxicillin therapy for 14 days which was followed by long term suppressive therapy with the same drug. Over 24 months of follow-up, he has done well without recurrence of infection. Another ICD was implanted on the contralateral side.

3.7  |  *Corynebacterium tuberculostearicum*

A 55-year-old woman with a history of arrhythmogenic right ventricular cardiomyopathy and sustained monomorphic ventricular tachycardia underwent dual chamber ICD implantation in 2006. She underwent pulse generator change in July 2013 during which a capsulectomy was performed and an antibiotic-eluting pouch was utilized. She began to notice worsening pain, swelling, redness, and drainage at the site without any fever 3 weeks after the procedure (Figure 2). She underwent system extraction. The ICD generator and the right atrial (RA) lead both grew *Corynebacterium tuberculostearicum* which was treated with oral clindamycin for 2 weeks. No other organisms were isolated. A subcutaneous defibrillator was implanted 3 days after extraction of the old system. Over 48 months of follow-up, the patient has not had any recurrent signs or symptoms of infection.

3.8  |  *Corynebacterium striatum*

A 55-year-old man with ischemic cardiomyopathy, history of dual chamber ICD implant in 2018, end stage renal disease and left ventricul- lar assist device (LVAD) as destination therapy, presented with atypical chest pain, generalized weakness, and worsening dyspnea for a week. He endorsed tenderness and drainage around the LVAD driveline insertion site. He denied fever. He had a history of chronic LVAD driveline site infection with *Corynebacterium* species and a recent admission for *Corynebacterium striatum* bacteremia that was being treated with oral cephalaxin. A TEE was performed and showed a moderate sized mobile echo density on the TV adjacent to the ICD lead. He underwent extraction of the CIED system which was followed by a 6-week course of intravenous vancomycin. Cultures from the RA and ICD leads grew *Corynebacterium striatum*. Long-term oral cephalaxin was recommended. The patient died 2 months after the procedure due to intracranial complications resulting from a fall on oral anticoagulation. No recurrent signs or symptoms of infection were reported.

3.9  |  *Stenotrophomonas maltophilia*

A 79-year-old man with a history of hypertension and complete heart block treated with permanent pacemaker (PPM) implantation in 2017, noted increasing irritation around his pacemaker incision site. He presented with pacemaker erosion and treatment was initiated with intravenous cefepime and vancomycin. He denied any fever or symptoms suggestive of systemic infection. The transvenous PPM system was subsequently extracted and replaced with a leadless pacemaker (Micra, Medtronic, Minneapolis, Minnesota, USA). The generator, RA lead and right ventricular (RV) lead cultures grew *Stenotrophomonas mal- tophilia* which was treated with oral trimethoprim-sulfamethoxazole for 6 weeks with resolution of symptoms. At 12 months of follow-up, he is doing well without any recurrent signs or symptoms of infection.
Descriptions of CIED infections with atypical microorganisms are limited to anecdotal case reports and to the best of our knowledge, this is the first study to systematically evaluate the clinical presentation, management and outcome in patients with CIED infection secondary to atypical pathogens.

The main findings in this paper are as follows: (1) Atypical pathogens accounted for 5% of CIED infections over a 10-year period (2) CIED infections secondary to atypical pathogens were associated with a good outcome if diagnosed early and treated with total system removal and tailored antimicrobial therapy. (3) This is the first report of CIED infection associated with *Kocuria* species, *Pseudozyma aphidis*, and isolated *Corynebacterium tuberculostearicum*.

The microbiology of CIED infection has changed over the last two decades. Hussein et al, reported the microbiology of CIED infection in a modern cohort of patients and found a significant rise in CIED infection secondary to methicillin-resistant staphylococcus aureus (MRSA). MRSA infections accounted for 34% of all CIED infections and 49% of all staphylococcal infections; atypical pathogens were found in less than 0.2%, however, an increasing trend was noted from the study period. CIED infection secondary to MRSA was associated with high mortality, especially in elderly patients with bacteremia. A high proportion of culture negative CIED infections which were not further characterized, lack of use of advanced laboratory methods such as 16S Ribosomal DNA sequence analysis and MALDI-TOF MS, and a different geographic location may account for the difference in prevalence of atypical CIED infections reported by Hussein et al and us.

Because CIED infections with atypical pathogens are rare, little is known about their presentation and outcome. Recent advancements in laboratory technology have allowed for microbial identification and diagnosis that was not previously possible. As a result, organisms historically not associated with CIED infections have now been isolated though the use of 16S ribosomal DNA sequencing as well as MALDI-TOF mass spectrometry. This is not unique to CIED infections; atypical pathogens have been identified through these means for multiple other types of infections, expanding our understanding of these organisms as pathogenic and not simple contaminants.

In our study, both patients with CIED infection due to *Pantoea* species presented with bacteremia. *Pantoea* species, which are members of Enterobacterales family, are gram-negative bacilli that are frequently found in soil and vegetation. Recent studies have also reported isolation of *Pantoea* species from the skin of healthy humans. In both immunocompetent and immunocompromised humans, Pantoea species are a rare cause of sepsis which at times can be multidrug resistant. One of our patients had no obvious risk factors for infection but the other had an long term PICC line which placed him at higher risk as *Pantoea* species have been associated with central venous catheter-associated infections. Cardiovascular infections with *Pantoea* species are exceedingly rare and only one patient with mitral valve endocarditis and another with CIED pocket infection have been reported to date. Most of the patients with *Pantoea* infection, including the two in our study, have done well following appropriate culture and sensitivity guided antimicrobial therapy. However, care should be exercised while using carbapenems as approximately 21% of *Pantoea agglomerans* isolates were noted to be carbapenem resistant in a recent series.

One of these patients was also co-infected with *Pseudozyma aphidis* which is a rare fungal cause of infection in immunocompromised patients, particularly in those with hematological and oncological disorders. A bloodstream infection via possible gastrointestinal translocation has been suggested as a source in a handful of patients that have been reported. Most of the reported patients responded to either voriconazole, posaconazole, or amphotericin B. CIED infection with *Pseudozyma aphidis* has not been reported to date.

One patient in our series had CIED infection due to *Kocuria* species which has not been previously reported. *Kocuria* species are gram-positive bacteria which are rarely associated with human disease. To date, only 28 patients with *Kocuria kristinae* infection, the most common pathogenic species, have been reported. These include patients with cholecystitis, peritonitis, abdominal abscess, bacteremia, umbilical sepsis, and urinary tract infection. Cardiac involvement in *Kocuria* infections is very rare and only four patients with *Kocuria* endocarditis have been reported. *Kocuria* species are often sensitive to vancomycin, linezolid, rifampicin, teicoplanin, cefotaxime, ampicillin/subactam, minocycline, and meropenem. Initial treatment of *Kocuria* infections should involve parenteral vancomycin in combination with another antibiotic to which the organism is susceptible.

The patient with *Cutibacterium acnes* CIED infection presented with a pocket-only infection. *Cutibacterium acnes* is a gram-positive bacterium that forms part of the normal flora of the skin and oral cavity. Although primarily recognized for its role in acne, *Cutibacterium acnes*, can cause a range of postoperative and device-related infections including those of cardiac shunts and prosthetics. *Cutibacterium acnes* native valve endocarditis is rare. To date, only four patients with *Cutibacterium acnes* mediated CIED infections have been reported. In most of those cases, the infection was indolent, difficult to diagnose and occurred after a long period following device implantation.

*Corynebacterium* species are gram-positive rods that colonize the skin and mucosal surfaces of humans. They are frequently isolated from clinical specimens and interpretation of their clinical relevance may be difficult. Lipophilic corynebacteria tend to be involved in infections of hospitalized patients and often show multidrug resistance. *Corynebacterium tuberculostearicum* has been associated with wound infection, urinary tract infection, osteomyelitis and mastitis. The species is often associated with resistance to multiple antimicrobials. To the best of our knowledge, there are no previous reports of isolated *Corynebacterium tuberculostearicum* mediated CIED infection. *Corynebacterium striatum* is an emerging multidrug resistant nosocomial pathogen capable of causing a variety of infections in immunocompromised and hospitalized patients. *Corynebacterium striatum* has been associated with both native and prosthetic valve endocarditis and bone and joint infections. However, CIED infections with *Corynebacterium striatum* are rare with only four patients reported to date. Our patient had a chronic LVAD driveline site infection.
and bacteremia which infected the CIED system. The characteristics of all the reported patients with Corynebacterium striatum CIED system infection are summarized in Table 2.

Stenotrophomonas maltophilia, a small, aerobic, gram-negative bacillus is a nosocomial pathogen extensively resistant to multiple antibiotics, and is also a rare cause of endocarditis. Because of its resistance to multiple antibiotics, Stenotrophomonas maltophilia endocarditis often results in frequent therapeutic failures and carries a high risk of complications and mortality. CIED infections with Stenotrophomonas maltophilia are highly unusual with only five patients reported to date.37,51,52,53,54 The characteristics of these patients are summarized in Table 2.

Our study had several limitations. This was a single center retrospective observational study from a quaternary care center. It is possible that the prevalence of bacterial colonization in the environment and on mucosal and skin surfaces differs between geographic regions. Our results therefore may not be automatically applicable to other geographic regions. Even though we utilized non-parametric methods of statistical analysis, larger multicenter collaborative efforts can provide datasets that lead to more robust comparisons between patients with typical and atypical CIED infections. Lastly, laboratory methods based on 16S ribosomal DNA sequencing as well as MALDI-TOF mass spectrometry were utilized for diagnosis in some but not all patients in our study. Prospective studies have shown that utilization of DNA analysis identified additional microbial species in 43% of patients with culture positive CIED infection and could therefore play a role in diagnosis of difficult to treat or culture negative CIED infections.

5 CONCLUSIONS

CIED infections with atypical pathogens were rare and associated with good outcome if diagnosed early and treated with total system removal and tailored antimicrobial therapy. Atypical pathogens cultured from blood, tissue or hardware in patients with CIED infection should be considered pathogens and not contaminants. Large multicenter studies are required to further characterize the determinants and outcomes in patients with atypical CIED infections.

ACKNOWLEDGMENTS

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CONFLICT OF INTEREST

None.

AUTHOR CONTRIBUTIONS

Drs. Kohli and Shahab were involved in data collection. Dr. Kohli carried out the analysis and wrote the initial draft. Drs. Shahab, Hazra, Aziz, Beaser, Upadhyay, Tung and Nayak took part in planning, writing, revising, and reviewing the final draft of this manuscript. All co-authors contributed fully in terms of the design of the study, the evaluation of data, the actual manuscript preparation, and the revision and approval of the final submitted manuscript. The corresponding author confirms that all authors have seen and approved the final text.

DATA AVAILABILITY STATEMENT

Some of the data underlying this article are available in the article. The authors will be happy to share the complete dataset upon request.

ORCID

Utkarsh Kohli MD 🌐 https://orcid.org/0000-0003-3410-840X
Ahmed Shahab MD 🌐 https://orcid.org/0000-0001-5997-1977
Andrew D. Beaser MD 🌐 https://orcid.org/0000-0001-7624-742X
Gaurav A. Upadhyay MD 🌐 https://orcid.org/0000-0002-3493-2100
Roderick Tung MD 🌐 https://orcid.org/0000-0002-8513-1303
Hemal M. Nayak MD 🌐 https://orcid.org/0000-0002-1899-079X

REFERENCES

1. Nielsen JC, Gerdes JC, Varma N. Infected cardiac-implantable electronic devices: prevention, diagnosis, and treatment. Eur Heart J. 2015;36:2484-2490.
2. Korantzopoulos P, Sideris S, Dilaveris P, Gatzoulis K, Goudevenos JA. Infection control in implantation of cardiac implantable electronic devices: current evidence, controversial points, and unresolved issues. Europace. 2016;18:473-478.
3. Padfield GJ, Steinberg C, Bennett MT, et al. Preventing cardiac implantable electronic device infections. Heart Rhythm. 2015;12:2344-2356.
4. Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2017;14:e503-e551.
5. Greenspon AJ, Rhim ES, Mark G, Desimone J, Ho RT. Lead-associated endocarditis: the important role of methicillin-resistant staphylococcus aureus. Pacing Clin Electrophysiol. 2008;31:548-553.
6. Hussein AA, Baghdy Y, Wazni OM, et al. Microbiology of cardiac implantable electronic device infections. JACC Clin Electrophysiol. 2016;2:498-505.
7. Kohli U, Aziz Z, Beaser AD, Nayak HM. A large deletion in RYR2 exon 3 is associated with nodolol and flecaainide refractory catecholaminergic polymorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2019;42:1146-1154.
8. Schröttner P, Gunzer F, Schüppel J, Rudolph WW. Identification of rare bacterial pathogens by 16S rRNA gene sequencing and MALDI-TOF MS. J Vis Exp. 2016;113:53176.
9. Singhal N, Kumar M, Kanaujia PK, Virdi JS. MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis. Front Microbiol. 2015;6:791.
10. DeMarco ML, Ford BA. Beyond identification: emerging and future uses for MALDI-TOF mass spectrometry in the clinical microbiology laboratory. Clin Lab Med. 2013;33:611-628.
11. Walterson AM, Pantoea SJ. Insights into a highly versatile and diverse genus within the enterobacteriaceae. FEMS Microbiol Rev. 2015;39:968-984.
12. Shami A, Al-Mijalli S, Pongchaikul P, Al-Barrag A, AbduRahim S. The prevalence of the culturable human skin aerobic bacteria in Riyadh, Saudi Arabia. BMC Microbiol. 2019;19:189.
13. Dutkiewicz J, Mackiewicz B, Kinga Lemieszek M, Golec M, Milanowski J. Pantoea agglomerans: a mysterious bacterium of evil and good. Part III. Deleterious effects: infections of humans, animals and plants. Ann Agric Environ Med. 2016;23:197-205.
14. Ageypong N, Govinden U, Owusu-Ofori A, Essack SY. Multidrug-resistant gram-negative bacterial infections in a teaching hospital in Ghana. Antimicrob Resist Infect Control. 2018;7:37.
15. Wong KW. Pantoea agglomerans as a rare cause of catheter-related infection in hemodialysis patients. J Vasc Access. 2013;14:306.
16. Habrińska-Zachwieja J, Krukowski J, Tubek S, Zeljaś A. Bacterial endocarditis caused by enterobacter agglomerans in a patient with mitral valve leaflet prolapse. Wiat Lek. 1989;42:453-455. (in Polish).
17. Ajam M, Shokr M, Ajam F, Lieberman R. Rare case of implantable cardioverter defibrillator infection caused by stenotrophomonas maltophilia and pantoea calida. BMJ Case Rep. 2019;12:e230506.
18. Büyükkam A. Tuncer Ö, Gür D, et al. Clinical and microbiological characteristics of Pantoea agglomerans infection in children. J Infect Public Health. 2018;11:304-309.
19. Telles JP, Ribeiro VST, Kraft L, Tuon FF. Pseudozyma spp. human infections: a systematic review. Med Mycol. 2020;59(1):1-6.
20. Napolitani M, Troiano G, Bedogni C, Messina G, Nante N. Kocuria kristinae: an emerging pathogen in medical practice. J Med Microbiol. 2019;68:1596-1603.
21. Garcia DC, Nascimento R, Soto V, Mendoza CE. A rare native mitral valve endocarditis successfully treated after surgical correction. BMJ Case Rep. 2014;2014:br2013202610.
22. Citro R, Prota C, Greco L, et al. Kocuria kristinae endocarditis related to diabetic foot infection. J Med Microbiol. 2013;62:932-934.
23. Lai CC, Wang JY, Lin SH, et al. Catheter-related bacteraemia and infective endocarditis caused by kocuria species. Clin Microbiol Infect. 2011;17:190-192.
24. Srinivasa KH, Agrawal N, Agarwal A, Manjunath CN. Dancing vegetations: kocuria rosea endocarditis. BMJ Case Rep. 2013:br2013010339.
25. Živković Žarić RS, Pejić AV, Janković SM, et al. Antimicrobial treatment of kocuria kristinae invasive infections: systematic review. J Chemother. 2019;31:109-119.
26. Perry A, Lambert P. Propionibacterium acnes: infection beyond the skin. Expert Rev Anti Infect Ther. 2011;9:1149-1156.
27. Banzon JM, Rehm SJ, Gordon SM, Hussain ST, Pettersson GB, Shrestha NK. Propionibacterium acnes endocarditis: a case series. Clin Microbiol Infect. 2017;23:396-399.
28. Hussain A, Nasir N, Jamil B. An unusual pathogen causing native valve endocarditis. J Ayub Med Coll Abbottabad. 2016;28:824-825.
29. Yamamoto R, Miyagawa S, Hagiya H, et al. Silent native-valve endocarditis caused by propionibacterium acnes. Intern Med. 2018;57:2417-2420.
30. Moehsen AH, Price A, Ridgway E, West JN, Green S, McKendrick MW. Propionibacterium acnes endocarditis in a native valve complicated by intraventricular abscess: a case report and review. Scand J Infect Dis. 2001;33:379-380.
31. Caballero Güeto J, Arana R, Calle G, del Rio EG, Sancho M, Straub C, Frei R, Goldenberger D. Propionibacterium tuberculostearicum: a potentially misidentified and multiresistant propionibacterium species isolated from clinical specimens. J Clin Microbiol. 2012;50:2561-2567.
32. Szemraj M, Kwaszewska A, Pawlak R, Szewczyk EM. Macrolide, lincomamide, and streptogramin B resistance in lipophilic propionibacterium inhabiting healthy human skin. Microb Drug Resist. 2014;20:404-409.
33. Datta P, Gupta V, Gupta M, Pal K, Chander J. Propionibacterium stenotrophomonas: an emerging nosocomial pathogen. Infect Disord Drug Targets. 2020;21(2):301-303.
34. Nudel K, Zhao X, Basu S, et al. Genomics of propionibacterium stenotrophomonas: an emerging multidrug-resistant pathogen of immunocompromised patients. Clin Microbiol Infect. 2018;24:1016.e7-1016.e13.
35. Rasmussen M, Mohlin AW, Nilson B. From contamination to infective endocarditis: a population-based retrospective study of propionibacterium isolated from blood cultures. Eur J Clin Microbiol Infect Dis. 2020;39:113-119.
36. Lee JY, Lee SH, Kim WH. Three-valve endocarditis caused by propionibacterium stenotrophomonas. Korean Circ J. 2018;48:861-862.
37. Nousair L, Salomon E, El Sayed F, et al. Monomicrobial bone and joint infection due to propionibacterium stenotrophomonas: review and treatment experiences. Clin Infect Dis. 2019;68:1596-1603.
38. Hinic V, Lang C, Weisser M, Straub C, Frei R, Goldenberger D. Propionibacterium tuberculostearicum: a potentially misidentified and multiresistant propionibacterium species isolated from clinical specimens. J Clin Microbiol. 2012;50:2561-2567.
39. Kalt F, Schulthess B, Siddler F, et al. Corynebacterium species rarely cause orthopedic infections. J Clin Microbiol. 2018;56:e01200-e01218.
40. Szemraj M, Kwaszewska A, Pawlak R, Szewczyk EM. Macrolide, lincomamide, and streptogramin B resistance in lipophilic propionibacterium inhabiting healthy human skin. Microb Drug Resist. 2014;20:404-409.
41. Lee JY, Lee SH, Kim WH. Three-valve endocarditis caused by propionibacterium stenotrophomonas. Korean Circ J. 2018;48:861-862.
42. Nousair L, Salomon E, El Sayed F, et al. Monomicrobial bone and joint infection due to propionibacterium stenotrophomonas: review and treatment experiences. Clin Infect Dis. 2019;68:1596-1603.
43. Hinic V, Lang C, Weisser M, Straub C, Frei R, Goldenberger D. Propionibacterium tuberculostearicum: a potentially misidentified and multiresistant propionibacterium species isolated from clinical specimens. J Clin Microbiol. 2012;50:2561-2567.
44. Rasmussen M, Mohlin AW, Nilson B. From contamination to infective endocarditis: a population-based retrospective study of propionibacterium isolated from blood cultures. Eur J Clin Microbiol Infect Dis. 2020;39:113-119.
45. Lee JY, Lee SH, Kim WH. Three-valve endocarditis caused by propionibacterium stenotrophomonas. Korean Circ J. 2018;48:861-862.
46. Nousair L, Salomon E, El Sayed F, et al. Monomicrobial bone and joint infection due to propionibacterium stenotrophomonas: review and treatment experiences. Clin Infect Dis. 2019;68:1596-1603.
47. Hinic V, Lang C, Weisser M, Straub C, Frei R, Goldenberger D. Propionibacterium tuberculostearicum: a potentially misidentified and multiresistant propionibacterium species isolated from clinical specimens. J Clin Microbiol. 2012;50:2561-2567.
48. Rasmussen M, Mohlin AW, Nilson B. From contamination to infective endocarditis: a population-based retrospective study of propionibacterium isolated from blood cultures. Eur J Clin Microbiol Infect Dis. 2020;39:113-119.
49. Lee JY, Lee SH, Kim WH. Three-valve endocarditis caused by propionibacterium stenotrophomonas. Korean Circ J. 2018;48:861-862.
50. Nousair L, Salomon E, El Sayed F, et al. Monomicrobial bone and joint infection due to propionibacterium stenotrophomonas: review and treatment experiences. Clin Infect Dis. 2019;68:1596-1603.
51. Takigawa M, Noda T, Kurita T, et al. Extremely late pacemaker-stenotrophomonas maltophilia endocarditis. J Ayub Med Coll Abbottabad. 2012;41:e21-e23.
52. Takigawa M, Noda T, Kurita T, et al. Extremely late pacemaker-stenotrophomonas maltophilia endocarditis. J Ayub Med Coll Abbottabad. 2012;41:e21-e23.
53. Takigawa M, Noda T, Kurita T, et al. Extremely late pacemaker-stenotrophomonas maltophilia endocarditis. J Ayub Med Coll Abbottabad. 2012;41:e21-e23.
54. Takigawa M, Noda T, Kurita T, et al. Extremely late pacemaker-stenotrophomonas maltophilia endocarditis. J Ayub Med Coll Abbottabad. 2012;41:e21-e23.
55. Takigawa M, Noda T, Kurita T, et al. Extremely late pacemaker-stenotrophomonas maltophilia endocarditis. J Ayub Med Coll Abbottabad. 2012;41:e21-e23.
56. Takigawa M, Noda T, Kurita T, et al. Extremely late pacemaker-stenotrophomonas maltophilia endocarditis. J Ayub Med Coll Abbottabad. 2012;41:e21-e23.
57. Takigawa M, Noda T, Kurita T, et al. Extremely late pacemaker-stenotrophomonas maltophilia endocarditis. J Ayub Med Coll Abbottabad. 2012;41:e21-e23.
54. Rostoff P, Paradowski A, Gackowski A, et al. Stenotrophomonas maltophilia pacemaker endocarditis in a patient with d-transposition of the great arteries after atrial switch procedure. *Int J Cardiol*. 2010;145:e92-5.

55. Pichlmairer M, Knigina L, Kuehn C, et al. The role of cohabitant unusual bacterial species in infection of cardiovascular implantable electronic devices (CIED). *Technol Health Care*. 2013;21:87-96.

**How to cite this article:** Kohli U, Hazra A, Shahab A, et al. Atypical pathogens associated with cardiac implantable electronic device infections. *Pacing Clin Electrophysiol*. 2021;44:1549–1561. [https://doi.org/10.1111/pace.14311](https://doi.org/10.1111/pace.14311)